Successful rescue of the neurogenic phenotype by inhibiting GR or inhibiting the formation of oxysterols with antioxidants pave the wave for potential therapies for the neurological defects observed in SLOS patients. The gene discussed is NR3C1; the disease is Smith-Lemli-Opitz syndrome.